Can Fite Biofarma (Can Fite Biofarma) Long-Term Capital Lease Obligation : $0.01 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Long-Term Capital Lease Obligation?

Can Fite Biofarma's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.01 Mil.

Can Fite Biofarma's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($0.02 Mil) to Sep. 2023 ($0.02 Mil) and declined from Sep. 2023 ($0.02 Mil) to Dec. 2023 ($0.01 Mil).

Can Fite Biofarma's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($0.07 Mil) to Dec. 2022 ($0.01 Mil) and declined from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.01 Mil).

Can Fite Biofarma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Can Fite Biofarma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Long-Term Capital Lease Obligation Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.04

0.02

0.07

0.01

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.01	0.01	0.02	0.02	0.01

Can Fite Biofarma (AMEX:CANF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Can Fite Biofarma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).